ULTRAGENYX PHARMACEUTICAL IN

Ultragenyx Pharmaceutical rises 12.27% in recent month, trading at $16.78 with a $1.7bn market cap—boosted by its rare‑disease drug pipeline.

Ultragenyx Pharmaceutical rises 2.75%—with a $1.6 bn market cap and rare‑disease focus, now at $16.75 per share, and a 52‑week high of $39.89.